CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Balloon Dilation of the Eustachian Tube

Policy governing medical necessity and coverage criteria for balloon dilation of the eustachian tube in adults with chronic obstructive eustachian tube dysfunction for Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyBalloon Dilation of the Eustachian Tube

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes in this revision

Effective DateMar 1, 2021

Next Review DateOct 16, 2024

Key ActionObtain prior authorization for Medicare Advantage and verify benefits; document comprehensive diagnostic assessment and failure of medical management before BDET.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥22 yrsage eligibility stated

69705,69706CPT codes covered when criteria met

Required (MA)prior auth

RCTs & SRsevidence base

2001-2020+refs years

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Medical necessity criteria

Covered when ALL of the following are met

Eligibility and symptom criteria: Adult age 22 years or older with symptoms of obstructive eustachian tube dysfunction (aural fullness that significantly affects quality of life or functional health status).

Objective findings: Abnormal tympanogram (Type B or C) and abnormal exam (e.g., retracted tympanic membrane, effusion, perforation, or other exam abnormality).

Diagnostic assessment: Comprehensive diagnostic assessment completed including patient-reported questionnaires, history and physical exam, tympanometry (if tympanic membrane intact), nasal endoscopy, and comprehensive audiometry.

Exclusion of other causes: Other causes of aural fullness (e.g., temporomandibular joint disorders, extrinsic obstruction of the eustachian tube, superior semicircular canal dehiscence, endolymphatic hydrops) have been ruled out.

Failure of medical management: Failure to respond to appropriate medical management of potential co-occurring conditions (e.g., allergic rhinitis, rhinosinusitis, laryngopharyngeal reflux), including 4–6 weeks of nasal steroid spray if indicated.

Tympanostomy history: If history of tympanostomy tube placement, symptoms should have improved while tubes were patent.

Reversibility demonstrated: Eustachian tube dysfunction shown to be reversible: performing Valsalva produces temporary improvement of tympanogram to Type A and provider visualizes lateral movement of the tympanic membrane on otoscopy.

Symptom pattern: Symptoms are continuous rather than episodic or only in response to barochallenge (e.g., only with flying).

No prior BDET: The individual has not had a previous balloon dilation of the eustachian tube (BDET) procedure.

The policy excludes individuals with conditions that cause extrinsic or non-dilatory eustachian tube dysfunction or that would contraindicate balloon dilation. Specifically excluded are patulous eustachian tube dysfunction; craniofacial syndromes (including cleft spectrum palate); history of radiation therapy to the nasopharynx; nasopharyngeal neoplasms or masses; enlarged adenoid pads producing extrinsic obstruction; neuromuscular disorders causing ineffective ET opening; and active systemic mucosal or autoimmune inflammatory diseases affecting the nasopharyngeal mucosa. Chronic, severe atelectatic ears are also listed as an exclusion.

Coverage and payment for services are governed by the member’s subscriber agreement and employer agreement, which take precedence over this medical policy. For member-specific benefits and eligibility, providers should contact the provider call center. Services determined not to be medically necessary or otherwise excluded by the member’s benefit documents may not be covered.

Patients who can reliably relieve middle-ear pressure by performing a Valsalva (i.e., demonstrate temporary normalization of the tympanogram to Type A and lateral tympanic membrane movement on otoscopy) are not appropriate candidates for BDET. Likewise, individuals with symptoms that are episodic only in response to barochallenge (for example, symptoms only during air travel) are excluded from coverage under the procedure criteria.

If a service is determined to be not medically necessary (or if a medically necessary service is a non-covered benefit under the member’s plan), the policy states that the provider may not bill the member unless the member has been informed and provided written agreement to accept financial responsibility in advance. Benefit documents and participation agreements should be consulted for applicable provisions.

Procedure Coding

Medically necessary CPT codes when criteria metCPTCovered

69705	Nasopharyngoscopy, surgical with dilation of eustachian tube (i.e., balloon dilation); unilateral
69706	Nasopharyngoscopy, surgical with dilation of eustachian tube (i.e., balloon dilation); bilateral

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products. Verify member benefits and eligibility with the provider call center prior to scheduling. Benefits and eligibility determined by the member's subscriber agreement, member certificate, and/or employer agreement supersede this policy.

Prior authorization required: Medicare Advantage
Prior authorization recommended: Commercial Products
Verify benefits and eligibility with provider call center; benefits documents supersede policy

Note

Prior Authorization / Benefit Check

Providers should verify member benefits and eligibility before providing services. The member’s subscriber agreement, member certificate, and/or employer agreement governs coverage and supersedes this medical policy. Contact the provider call center for member-specific benefit information.

Benefits and eligibility are determined by subscriber agreement/member certificate/employer agreement

Clinical Background

The eustachian tube ventilates the middle ear, clearing secretions and equalizing pressure. Chronic obstructive eustachian tube dysfunction (ETD) occurs when the tubal valve fails to open or close properly, producing symptoms such as aural fullness, pressure, hearing changes, and otalgia that may be persistent or provoked by barometric stress. Balloon dilation of the eustachian tube (BDET) is a transnasal endoscopic tuboplasty in which a saline‑filled balloon catheter is introduced into the cartilaginous portion of the tube and inflated to dilate the lumen (typically with inflation maintained for about two minutes). The procedure is intended to improve tubal patency and is performed under general or monitored anesthesia and may be combined with other middle-ear procedures when indicated.

Key Definitions

inv-16: Definition — Balloon dilation of the eustachian tube (BDET)

TermBalloon dilation of the eustachian tube (BDET)

DefinitionA transnasal, minimally invasive endoscopic tuboplasty in which a saline-filled balloon catheter is introduced into the cartilaginous eustachian tube and inflated to produce local dilation; pressure is typically maintained for about 2 minutes before deflation and removal.

Typical setting/anesthesiaUsually performed under general anesthesia; may be performed as standalone or with concurrent procedures (e.g., adenoidectomy, septoplasty, turbinate surgery, myringotomy/tympanostomy).

Regulatory/device examplesMultiple devices have received de novo 510(k) classification (examples: Acclarent Eustachian Tube Balloon Dilation System, Aera, Xpress ENT, Nuvent, Audion ET, Vensure).

inv-17: Definition — Patulous eustachian tube dysfunction (listed as contraindication)

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyBalloon Dilation of the Eustachian Tube

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes in this revision

Effective DateMar 1, 2021

Next Review DateOct 16, 2024

Key ActionObtain prior authorization for Medicare Advantage and verify benefits; document comprehensive diagnostic assessment and failure of medical management before BDET.

SourceLink

On This Page

Provider call center is the source for member-specific benefit verification

Policy is informational and does not guarantee payment

Denial Risk

Member Financial Liability and Denials

Denials for services not meeting medical criteria may result in member financial liability. If a service is determined to be not medically necessary or is a non-covered benefit, providers may not bill the member unless the member has been informed in advance and has agreed in writing to accept financial responsibility. Refer to participation agreements for applicable provisions.

Denials may result in member liability
Provider may not charge member unless informed and written agreement obtained in advance
Refer to provider participation agreement for billing rules

Step Therapy

Step Therapy / Medical Management

No formal step-therapy rules are specified in this policy. The policy references multiple conservative treatments and medical management that should be attempted and documented (for example, 4–6 weeks of nasal steroid spray when indicated) before considering procedural intervention.

No formal step therapy protocol specified
Documented failure of appropriate medical management (e.g., 4–6 weeks of nasal steroid spray when indicated) is required
Multiple conservative treatments should be tried and documented prior to procedure

Patulous eustachian tube dysfunction (patulous ETD)

Clinical featuresSuggested by autophony of voice, audible respirations, pulsatile tinnitus, and/or aural fullness.

Policy roleListed as a contraindication to balloon dilation of the eustachian tube (BDET).

Related exclusionsPatients with patulous ETD are excluded from BDET; other exclusion categories include craniofacial syndromes, prior nasopharyngeal radiation, nasopharyngeal neoplasms, enlarged adenoids causing extrinsic obstruction, neuromuscular disorders impairing ET opening, and active systemic mucosal autoimmune disease.

inv-18: Definition — Balloon eustachian tuboplasty (endoluminal dilation) description

TermBalloon eustachian tuboplasty (endoluminal dilation)

Procedure descriptionEndoluminal dilation of the eustachian tube using a balloon catheter introduced transnasally via endoscopy to dilate the cartilaginous eustachian tube and improve patency.

Procedure detailsBalloon is inflated with saline, pressure maintained for approximately 2 minutes, then emptied and removed; may be performed under general anesthesia and in combination with other ear/nose procedures.

Evidence contextStudied in randomized trials, systematic reviews, histopathology and mechanism studies, and observational series; described in multiple specialty publications and guidance on in-office and operative techniques.